Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.405 USD | -1.06% | +1.81% | -87.07% |
04-17 | Truist Adjusts Marinus Pharmaceuticals' PT to $10 From $25, Keeps Buy Rating | MT |
04-16 | Baird Downgrades Marinus Pharmaceuticals to Neutral, Price Target at $2 | MT |
Sales 2024 * | 41.06M 56.12M | Sales 2025 * | 62.09M 84.87M | Capitalization | 77.17M 105M |
---|---|---|---|---|---|
Net income 2024 * | -133M -182M | Net income 2025 * | -93M -127M | EV / Sales 2024 * | 1.88 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.24 x |
P/E ratio 2024 * |
-0.63
x | P/E ratio 2025 * |
-1.07
x | Employees | 166 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.02% |
Latest transcript on Marinus Pharmaceuticals, Inc.
1 day | -1.06% | ||
1 week | +1.81% | ||
Current month | -84.46% | ||
1 month | -84.02% | ||
3 months | -85.98% | ||
6 months | -78.94% | ||
Current year | -87.07% |
Managers | Title | Age | Since |
---|---|---|---|
Scott Braunstein
CEO | Chief Executive Officer | 60 | 18-09-04 |
Steven Pfanstiel
DFI | Director of Finance/CFO | 51 | 21-04-11 |
Joseph Hulihan
CTO | Chief Tech/Sci/R&D Officer | 68 | 19-11-05 |
Members of the board | Title | Age | Since |
---|---|---|---|
Tim Mayleben
BRD | Director/Board Member | 63 | 08-11-30 |
Scott Braunstein
CEO | Chief Executive Officer | 60 | 18-09-04 |
Elan Ezickson
BRD | Director/Board Member | 60 | 19-12-11 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.96% | 11 M€ | -6.03% | - | |
0.02% | 0 M€ | 0.00% | - | |
0.02% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 1.405 | -1.06% | 1,136,344 |
24-04-25 | 1.42 | -1.39% | 1,350,534 |
24-04-24 | 1.44 | 0.00% | 1,651,847 |
24-04-23 | 1.44 | -2.37% | 2,871,897 |
24-04-22 | 1.475 | +6.88% | 3,257,216 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-87.07% | 77.17M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- MRNS Stock